Last reviewed · How we verify
Secretome
Secretome is a Biologic drug developed by Yohanes Firmansyah, dr, MH, MM. It is currently in Phase 2 development. Also known as: hepatoprotector drugs, ursodeoxycholic acid, secretome, hucmsc.
The secretome refers to the set of proteins expressed by an organism and secreted into the extracellular space, including cytokines, growth factors, and extracellular matrix proteins. Autologous hair follicle-derived secretome is being studied in clinical trials for various conditions, including facial aging and rejuvenation, polycystic ovary syndrome, and stem cell banking.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Secretome |
|---|---|
| Also known as | hepatoprotector drugs, ursodeoxycholic acid, secretome, hucmsc, Messenchymal stem cell Concitioned Media |
| Sponsor | Yohanes Firmansyah, dr, MH, MM |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy of Formulation for Improving Vagina Laxity: A Pilot Study (NA)
- Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures
- Mesenchymal Stem Cells (MSCs) and Conditioned Medium Mesenchymal Stem Cells as Adjuvant Therapy for Sepsis (PHASE1, PHASE2)
- Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer (PHASE1, PHASE2)
- Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Acute Stroke Infarct (PHASE1, PHASE2)
- Stem Cells and Secretomes for Infertility Therapy in Polycystic Ovary Syndrome (PCOS) Patients With Insulin Resistance. (PHASE1, PHASE2)
- Mesenchymal Stem Cell Therapy (MSCs) and Conditioned Medium Therapy for Osteoartrithis (PHASE1, PHASE2)
- Secretome vs. PRP Injections for Hair Density and Growth in Androgenetic Alopecia Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secretome CI brief — competitive landscape report
- Secretome updates RSS · CI watch RSS
- Yohanes Firmansyah, dr, MH, MM portfolio CI
Frequently asked questions about Secretome
What is Secretome?
Who makes Secretome?
Is Secretome also known as anything else?
What development phase is Secretome in?
Related
- Manufacturer: Yohanes Firmansyah, dr, MH, MM — full pipeline
- Therapeutic area: All drugs in Other
- Also known as: hepatoprotector drugs, ursodeoxycholic acid, secretome, hucmsc, Messenchymal stem cell Concitioned Media
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing